How effective is this new peptide pen?

What you need to know about the GHK-Cu pen

- DR. KAYCEE REYES

After the topical copper peptide wave hit Manila, the next frontier has quietly arrived: GHK-Cu in injectable form, marketed as a “peptide pen” by overseas longevity sites and resold by local importers.

The pitch is simple. If a serum gives modest results, surely a subcutaneous injection would give more. It is the same logic that pushed glutathione from oral to IV in this country a decade ago.

The answer is more complicated than the marketing.

First, the basics. There is no prefilled pen like Ozempic or Wegovy that comes in a pen. What people call a “GHK-Cu pen” is a lyophilized vial of copper peptide that you reconstitute yourself and draw into an insulin syringe. No GHK-Cu injectable is approved as a drug by the US FDA, the European Medicines Agency, or the Philippine FDA. In the US, injectable GHK-Cu has been moving in and out of the FDA’s 503A compounding categories through 2026, with a Pharmacy Compounding Advisory Committee meeting scheduled before February 2027 to decide its fate. Until then, no licensed American pharmacy has a clean legal path to compound it for injection. Locally, Republic Act 9711 requires every injectable to carry a Certificate of Product Registration. The vials being sold on Filipino peptide sites and shipped from abroad do not have one.